Paper Details

  1. Home
  2. Paper Details

A Review of the Cardiovascular Safety of Prucalopride in Patients With Chronic Idiopathic Constipation.

Author: BoulesMena, DerakhchanKatayoun, GabrielAndré, KoweyPeter R, KreidiehBahij, SpaldingWilliam, TackJan, TerreriBrian, YoussefAshraf

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This review summarizes CV safety data for prucalopride, a high-affinity 5-HT 4 agonist approved in the United States in 2018 for adults with CIC. No significant effects of prucalopride on CV safety were observed in animal models or early-phase clinical studies. Studies to date have not raised concerns regarding the impact of prucalopride treatment on CV parameters.
Paper Details　
Original Abstract of the Article :
Prokinetic agents, specifically 5-hydroxytryptamine type 4 (5-HT 4 ) receptor agonists, have been shown to provide relief in chronic idiopathic constipation (CIC). The first-generation 5-HT 4 agonists were initially withdrawn from use owing to associations with serious cardiovascular (CV) events. Th...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226463/

データ提供：米国国立医学図書館（NLM）

Prucalopride: Navigating the Cardiovascular Desert of Constipation

This research guides us through the often uncomfortable and sometimes debilitating world of [chronic idiopathic constipation (CIC)]. It's like navigating a vast desert of bowel dysfunction, where you're searching for a smooth and efficient journey. The study focuses on the cardiovascular safety of [prucalopride], a high-affinity [5-hydroxytryptamine type 4 (5-HT4)] receptor agonist approved for treating CIC.

A Safe Passage: Prucalopride's Cardiovascular Profile

The research reviews extensive data, including animal studies, early-phase clinical trials, and large-scale observational studies, demonstrating that prucalopride appears to be safe for cardiovascular health. The study found no significant adverse cardiovascular events in patients treated with prucalopride, even at therapeutic and supratherapeutic doses. This is like having a trusty camel that can traverse the desert safely, even when carrying a heavier load than usual.

Hope for a Common Condition

This research offers hope for individuals struggling with CIC, a condition that affects a significant portion of the population. The findings suggest that prucalopride can provide relief from constipation without significant cardiovascular risks. This is a welcome development in the search for effective and safe treatment options for a common and often uncomfortable condition.

Health Implications and Everyday Life

Constipation is a common issue, but it can have a significant impact on quality of life. If you experience constipation, it's crucial to consult with your healthcare provider to discuss potential causes and treatment options. Lifestyle changes, such as increasing fiber intake and staying hydrated, are often the first line of defense. In some cases, medications like prucalopride may be recommended.

Dr.Camel's Conclusion

This research provides reassurance for individuals with CIC who are considering prucalopride as a treatment option. It's a testament to the importance of rigorous research and thorough safety evaluations in ensuring the safety and efficacy of medications. This research offers hope for a future where constipation is no longer a source of discomfort and embarrassment.
Date :
  1. Date Completed 2023-06-02
  2. Date Revised 2023-07-18
Further Info :

Pubmed ID

36927957

DOI: Digital Object Identifier

PMC10226463

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.